The San Diego-based company expects to make its latest CGM technology available to Canadians on Oct. 10, 2023. It covers people with all types of diabetes aged two and older, including those who are pregnant, in the country.
G7 received FDA clearance in December 2022 and Dexcom launched the device in the U.S. in February of this year.
The Dexcom CGM takes the guesswork out of managing diabetes. It enables the visibility of glucose levels and their direction at a glance. This gives users the ability to make smarter decisions in the moment, taking better control of their condition.
“From what I’ve seen in my practice, people with diabetes are most often looking for a simple but effective solution to management that limits the impact on their everyday life,” said Dr. Ilana Halperin, chief medical information officer and endocrinologist, Sunnybrook Health Sciences Centre. “Dexcom G7 delivers on that promise and will allow both patients and healthcare providers to work together on improving their care with a tool backed by health data and proven results.”
More about the Dexcom G7
Key features include wearability — it’s the smallest Dexcom sensor, designed for a comfortable and discreet wear. Its easy insertion process includes a simple, painless one-push applicator with the all-in-one sensor and no assembly required. G7 has a fast sensor warm-up time (30 minutes) and 96% of users called the system “easy to use.”
Dexcom designed G7 to send real-time glucose readings automatically to a compatible display device. It requires no routine fingersticks, scanning or calibration. The system also has a predictive alert, notifying users up to 20 minutes in advance of severe hypoglycemia.
Remote monitoring enables the sharing of glucose data with up to 10 followers, while a 12-hour grace period makes sensor replacement more convenient. Dexcom also said its G7 becomes the first waterproof CGM available in Canada. It can be submerged under eight feet of water for up to 24 hours.
“CGM has become the standard of care for diabetes management for good reason,” said André Côté, VP and GM, Dexcom Canada. “We strongly believe that Canadians who are now able to access Dexcom G7 CGM will immediately benefit from the improved accuracy and easy-to-adopt user experience, while finding comfort in the trusted technology that Dexcom has pioneered.
“Our top priority will always be to empower those living with diabetes to make more insightful decisions about food, activity, and treatment in a simple and effective way, and Dexcom G7 allows us to achieve that with more impact than ever before.”
